160 related articles for article (PubMed ID: 37388210)
21. Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study.
Park S; Kim WG; Han M; Jeon MJ; Kwon H; Kim M; Sung TY; Kim TY; Kim WB; Hong SJ; Shong YK
Thyroid; 2017 Sep; 27(9):1164-1170. PubMed ID: 28699428
[TBL] [Abstract][Full Text] [Related]
22. 2015 American Thyroid Association guidelines and thyroid-stimulating hormone suppression after thyroid lobectomy.
Reed R; Strumpf A; Martz TG; Kavanagh KJ; Fedder KL; Jameson MJ; Shonka DC
Head Neck; 2021 Feb; 43(2):639-644. PubMed ID: 33124116
[TBL] [Abstract][Full Text] [Related]
23. The magnitude of increased Levothyroxine dose during pregnancy in patients on thyroid-stimulating hormone (TSH) suppression treatment after total thyroidectomy for papillary carcinoma.
Minakata M; Ito M; Kishi T; Hada M; Masaki Y; Nakamura T; Kousaka K; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
Endocr J; 2022 Feb; 69(2):165-172. PubMed ID: 34526424
[TBL] [Abstract][Full Text] [Related]
24. Optimal thyrotropin level for low-risk papillary thyroid carcinoma after ultrasound-guided radiofrequency ablation.
Li X; Yan L; Xiao J; Li Y; Zhu Y; Yang Z; Zhang M; Luo Y
Int J Hyperthermia; 2023; 40(1):2160880. PubMed ID: 36599433
[TBL] [Abstract][Full Text] [Related]
25. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
[TBL] [Abstract][Full Text] [Related]
26. The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study.
Dou Y; Chen Y; Hu D; Su X
Front Endocrinol (Lausanne); 2020; 11():619841. PubMed ID: 33633689
[TBL] [Abstract][Full Text] [Related]
27. Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer.
Klubo-Gwiezdzinska J; Auh S; Gershengorn M; Daley B; Bikas A; Burman K; Wartofsky L; Urken M; Dewey E; Smallridge R; Chindris AM; Kebebew E
JAMA Netw Open; 2019 Feb; 2(2):e187754. PubMed ID: 30707227
[TBL] [Abstract][Full Text] [Related]
28. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
[TBL] [Abstract][Full Text] [Related]
29. Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients.
Yavuz DG; Yazan CD; Hekimsoy Z; Aydin K; Gokkaya N; Ersoy C; Akalın A; Topaloglu O; Aydogan BI; Dilekci ENA; Alphan Uc Z; Cansu GB; Ozsari L; Iyidir OT; Olgun ME; Keskin L; Mert M; Can B; Gungor K; Galip T; Cantürk Z; Elbuken G; Pekkolay Z; Kutbay NO; Yorulmaz G; Kalkan AT; Unsal YA; Yay A; Karagun B; Bozkur E
Clin Endocrinol (Oxf); 2022 Dec; 97(6):833-840. PubMed ID: 35639050
[TBL] [Abstract][Full Text] [Related]
30. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Biondi B; Cooper DS
Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
[TBL] [Abstract][Full Text] [Related]
31. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
32. Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients.
Ito M; Miyauchi A; Kang S; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nakamura H; Amino N
Eur J Endocrinol; 2015 Sep; 173(3):333-40. PubMed ID: 26077156
[TBL] [Abstract][Full Text] [Related]
33. Fasting serum glucose, thyroid-stimulating hormone, and thyroid hormones and risk of papillary thyroid cancer: A case-control study.
Hu MJ; Zhang C; Liang L; Wang SY; Zheng XC; Zhang Q; Jiang CX; Zhong Q; Huang F
Head Neck; 2019 Jul; 41(7):2277-2284. PubMed ID: 30759328
[TBL] [Abstract][Full Text] [Related]
34. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
[TBL] [Abstract][Full Text] [Related]
35. A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol.
Lee EK; Kang YE; Park YJ; Koo BS; Chung KW; Ku EJ; Won HR; Yoo WS; Jeon E; Paek SH; Lee YS; Lim DM; Suh YJ; Park HK; Kim HJ; Kim BH; Kim M; Kim SW; Yi KH; Park SK; Jung EJ; Choi JY; Bae JS; Hong JH; Nam KH; Lee YK; Yu HW; Go S; Kang YM;
Endocrinol Metab (Seoul); 2021 Jun; 36(3):574-581. PubMed ID: 34034365
[TBL] [Abstract][Full Text] [Related]
36. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.
Santoro AB; Vargens DD; Barros Filho Mde C; Bulzico DA; Kowalski LP; Meirelles RM; Paula DP; Neves RR; Pessoa CN; Struchine CJ; Suarez-Kurtz G
Br J Clin Pharmacol; 2014 Nov; 78(5):1067-75. PubMed ID: 24910925
[TBL] [Abstract][Full Text] [Related]
37. Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults.
Brito JP; Deng Y; Ross JS; Choi NH; Graham DJ; Qiang Y; Rantou E; Wang Z; Zhao L; Shah ND; Lipska KJ
JAMA Intern Med; 2022 Apr; 182(4):418-425. PubMed ID: 35226058
[TBL] [Abstract][Full Text] [Related]
38. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
39. Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid Cancer.
Schumm MA; Lechner MG; Shu ML; Ochoa JE; Kim J; Tseng CH; Leung AM; Yeh MW
Endocr Pract; 2021 Jul; 27(7):691-697. PubMed ID: 33642257
[TBL] [Abstract][Full Text] [Related]
40. Free thyroxine, free triiodothyronine, and thyrotropin concentrations in hypothyroid and thyroid carcinoma patients receiving thyroxine therapy.
Liewendahl K; Helenius T; Lamberg BA; Mähönen H; Wägar G
Acta Endocrinol (Copenh); 1987 Nov; 116(3):418-24. PubMed ID: 3687325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
